Your Good Partner in Biology Research

重組蛋白

產(chǎn)品名稱 貨號(hào) 規(guī)格
Recombinant Delftia acidovorans 50S ribosomal protein L18 (rplR) CSB-YP433543DHV
CSB-EP433543DHV
CSB-BP433543DHV
CSB-MP433543DHV
CSB-EP433543DHV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Delftia acidovorans Orotidine 5'-phosphate decarboxylase (pyrF) CSB-YP433544DHV
CSB-EP433544DHV
CSB-BP433544DHV
CSB-MP433544DHV
CSB-EP433544DHV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Delftia acidovorans PKHD-type hydroxylase Daci_1172 (Daci_1172) CSB-YP433545DHV
CSB-EP433545DHV
CSB-BP433545DHV
CSB-MP433545DHV
CSB-EP433545DHV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Delftia acidovorans (Dimethylallyl)adenosine tRNA methylthiotransferase MiaB CSB-YP433546DHV
CSB-EP433546DHV
CSB-BP433546DHV
CSB-MP433546DHV
CSB-EP433546DHV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Delftia acidovorans Bis (5'-nucleosyl)-tetraphosphatase, symmetrical CSB-YP433547DHV
CSB-EP433547DHV
CSB-BP433547DHV
CSB-MP433547DHV
CSB-EP433547DHV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Delftia acidovorans Fructose-1,6-bisphosphatase class 1 (fbp) CSB-YP433548DHV
CSB-EP433548DHV
CSB-BP433548DHV
CSB-MP433548DHV
CSB-EP433548DHV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Delftia acidovorans Tetraacyldisaccharide 4'-kinase (lpxK) CSB-YP433549DHV
CSB-EP433549DHV
CSB-BP433549DHV
CSB-MP433549DHV
CSB-EP433549DHV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Delftia acidovorans UDP-N-acetylglucosamine 1-carboxyvinyltransferase (murA) CSB-YP433550DHV
CSB-EP433550DHV
CSB-BP433550DHV
CSB-MP433550DHV
CSB-EP433550DHV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Delftia acidovorans 10 kDa chaperonin (groS) CSB-YP433551DHV
CSB-EP433551DHV
CSB-BP433551DHV
CSB-MP433551DHV
CSB-EP433551DHV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Delftia acidovorans Glycine--tRNA ligase alpha subunit (glyQ) CSB-YP433552DHV
CSB-EP433552DHV
CSB-BP433552DHV
CSB-MP433552DHV
CSB-EP433552DHV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Delftia acidovorans Probable intracellular septation protein A (Daci_3300), partial CSB-YP433553DHV1
CSB-EP433553DHV1
CSB-BP433553DHV1
CSB-MP433553DHV1
CSB-EP433553DHV1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Delftia acidovorans Alanine--tRNA ligase (alaS), partial CSB-YP433554DHV
CSB-EP433554DHV
CSB-BP433554DHV
CSB-MP433554DHV
CSB-EP433554DHV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Delftia acidovorans Gamma-glutamyl phosphate reductase (proA) CSB-YP433555DHV
CSB-EP433555DHV
CSB-BP433555DHV
CSB-MP433555DHV
CSB-EP433555DHV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Delftia acidovorans ATP-dependent Clp protease ATP-binding subunit ClpX (clpX) CSB-YP433556DHV
CSB-EP433556DHV
CSB-BP433556DHV
CSB-MP433556DHV
CSB-EP433556DHV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Delftia acidovorans 50S ribosomal protein L20 (rplT) CSB-YP433557DHV
CSB-EP433557DHV
CSB-BP433557DHV
CSB-MP433557DHV
CSB-EP433557DHV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Agrobacterium tumefaciens Cell division protein FtsQ (ftsQ), partial CSB-YP433558AYS
CSB-EP433558AYS
CSB-BP433558AYS
CSB-MP433558AYS
CSB-EP433558AYS-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Agrobacterium tumefaciens NADH-quinone oxidoreductase subunit C (nuoC) CSB-YP433559AYS
CSB-EP433559AYS
CSB-BP433559AYS
CSB-MP433559AYS
CSB-EP433559AYS-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Agrobacterium tumefaciens Dihydroorotate dehydrogenase (quinone) CSB-YP433560AYS
CSB-EP433560AYS
CSB-BP433560AYS
CSB-MP433560AYS
CSB-EP433560AYS-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Agrobacterium fabrum N-acyl homoserine lactonase AiiB (aiiB) CSB-YP433561AYS
CSB-EP433561AYS
CSB-BP433561AYS
CSB-MP433561AYS
CSB-EP433561AYS-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Enterocytozoon bieneusi Probable glutamate--tRNA ligase, cytoplasmic (EBI_22577), partial CSB-YP433562EMA
CSB-EP433562EMA
CSB-BP433562EMA
CSB-MP433562EMA
CSB-EP433562EMA-B
20μg/100μg/1mg(1mg*1 or 500ug*2)

有用資源

什么是重組蛋白?

重組蛋白是一種可操縱的蛋白質(zhì)形式,可以通過(guò)多種方式產(chǎn)生大量蛋白質(zhì)、修改基因序列和制造有用的商業(yè)產(chǎn)品。重組蛋白的技術(shù)資源在重組蛋白的開發(fā)過(guò)程中,除了表達(dá)系統(tǒng)之外,還面臨著一系列令人困惑的選擇,如表達(dá)載體的選擇、表達(dá)蛋白的長(zhǎng)度(全長(zhǎng)或部分)、是否帶標(biāo)簽等。在生產(chǎn)重組蛋白時(shí),你必須做出很多決定。如果你選擇的明智,你將獲得高質(zhì)量的重組蛋白,后續(xù)的實(shí)驗(yàn)更有可能成功。但是如果你做了錯(cuò)誤的決定,你可能得不到你所需要的重組蛋白或者重組蛋白的質(zhì)量和純度不符合要求。在這里,來(lái)自CUSABIO的蛋白表達(dá)工程師根據(jù)他們開發(fā)重組蛋白的經(jīng)驗(yàn)總結(jié)出了幾個(gè)有用的提示,可以幫助你做出明智的決策。

第一條:重組蛋白的生產(chǎn),在這篇文章中,我們旨在闡明重組蛋白的定義以及如何生產(chǎn)重組蛋白。

第二條:如何選擇合適的表達(dá)載體?

表達(dá)載體是一種DNA分子,它攜帶特定的基因進(jìn)入宿主細(xì)胞,并利用細(xì)胞的蛋白質(zhì)合成機(jī)制來(lái)產(chǎn)生由該基因編碼的蛋白質(zhì)。表達(dá)載體可使外源基因在宿主細(xì)胞中高效表達(dá),經(jīng)過(guò)多年的發(fā)展,表達(dá)載體已成為一種成熟而受歡迎的生物技術(shù)。在重組蛋白生產(chǎn)過(guò)程中是一種基本成分。正如標(biāo)題所示,本文主要總結(jié)了幾個(gè)有用的技巧來(lái)選擇合適的表達(dá)載體。

第三條:如何表達(dá)具有生物活性的蛋白質(zhì)?

根據(jù)重組蛋白的不同應(yīng)用,對(duì)其生物活性有不同的要求。但是我們?nèi)绾未_保蛋白質(zhì)的產(chǎn)生具有生物活性呢?本文將圍繞這個(gè)主題,并提供一些解決方案。除了以上文章,我們還收集了一些重組蛋白的常見問(wèn)題。您可以單擊以下鏈接查看。http://m.cstxtech.com/technology-91.html。此外,我們還為我們的客戶提供重組蛋白表達(dá)服務(wù),您可以點(diǎn)擊這里獲取更多信息。注:如果您對(duì)CUSABIO的蛋白質(zhì)有任何疑問(wèn),涉及到蛋白質(zhì)的價(jià)格、交貨、質(zhì)量等,您可以點(diǎn)擊橙色按鈕為我們?cè)诰€留言。

引用資料

Recombinant Severe acute respiratory syndrome coronavirus 2 RNA-dependent RNA polymerase(NSP12) cited in "SARS-CoV-2 hijacks cellular kinase CDK2 to promote viral RNA synthesis". Signal transduction and targeted therapy, 2023

Recombinant Mouse Mixed lineage kinase domain-like protein(Mlkl) cited in "OASL phase condensation induces amyloid-like fibrillation of RIPK3 to promote virus-induced necroptosis". Nature cell biology, 2023

Recombinant Mouse Proto-oncogene c-Fos(Fos) cited in "Dihydroartemisinin imposes positive and negative regulation on Treg and plasma cells via direct interaction and activation of c-Fos". Communications biology, 2023

Recombinant Human Keratin, type I cytoskeletal 18(KRT18) cited in "Calcitonin gene-related peptide ameliorates sepsis-induced intestinal injury by suppressing NLRP3 inflammasome activation". International immunopharmacology, 2023

Recombinant Human Protein Wnt-5a (WNT5A) cited in "ATBF1 is a potential diagnostic marker of histological grade and functions via WNT5A in breast cancer". BMC Cancer, 2022

Read More >>